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Abstract  
Objective: To provide the first estimate of the cost effectiveness of financial incentive for 
breastfeeding intervention compared with usual care. 
 
Design: Within-cluster (‘ward’ level)  RCT cost-effectiveness analysis.  
 
Setting: Five local authority districts in the north of England 
 
Participants: 5,398 mother-infant dyads (intervention arm), 4612 mother-infant dyads (control arm) 
 
Interventions: Offering a financial incentive (over a 6 month period) on breastfeeding to women 
living in areas with low breastfeeding prevalence (<40% at 6–8 weeks) 
 
Main outcome measures: Babies breastfed (receiving breastmilk) at 6–8week, and cost per  
additional baby breastfed  
 
Methods: Costs were compared to differences in area level data on babies’ breastfed in order to  
estimate a cost per additional baby breastfed and the quality adjusted life year (QALY) gains  
required over the lifetime of babies to justify intervention cost.    
 
Results: In the trial, the total cost of providing the intervention in 46 wards was £462,600, with an 
average cost per ward of £9,989 and per baby of £91. At follow up, area-level breastfeeding 
prevalence at 6-8 weeks was 31.7% (95% CI, 29.4-34.0) in control areas and 37.9% (95% CI, 35.0-
40.8) in intervention areas. The adjusted difference between intervention and control was 5.7 
percentage points (95% CI, 2.7-8.6; P < .001), resulting in 10 (95% CI 6 to 14) more additional babies 
breastfed in the intervention wards (39 vs 29). 
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The cost per additional baby breastfed at 6-8 weeks was £974. At a cost per QALY threshold of 
£20,000 (recommended in England), an additional breastfed baby would need to show a QALY gain 
of 0.05 over their lifetime to justify the intervention cost.  If decision-makers are willing to pay £974 
(or more) per additional baby breastfed, then this intervention is cost-effective. Results were robust to 
sensitivity analyses.   
 
Conclusion: This study provides information to help inform public health guidance on breastfeeding. 
To make the economic case unequivocal, evidence on the varied and long-term health benefits of 
breastfeeding to both the baby and mother and the effectiveness of financial incentives for 
breastfeeding beyond 6-8 weeks is required.  
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What is already known on this topic?  
 There is evidence that incentive based breastfeeding programmes can increase breastfeeding 
in areas with low rates.   
 
 Solid evidence of the value for money of these programmes is lacking despite calls for such 
evidence.   
 
What this study adds 
 This study reports, for the first time, cost effectiveness estimates of the offer of a financial 
incentive for breastfeeding in areas with low breastfeeding rates.  
 
 This study provides new and high quality data from a large cluster RCT (with 92% follow up 
data), with resource use data collected prospectively. 
 
 Our study shows that these programmes can increase breastfeeding and provide good value 
for money if decision makers are willing to pay £974(or more) per additional baby receiving 
breastmilk. 
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Introduction  
Breastfeeding has benefits for both mothers and babies.[1] However, rates of any (i.e. exclusive and 
mixed) breastfeeding at age 12 months, are below 20%, on average, in high income countries. The 
UK has the lowest rate (0.5%), Oman the highest (95%) and the USA has a rate of 27%. [2] Even in 
low- and middle-income countries with relatively higher breastfeeding rates at age 12 months, only 4 
out of 10 babies younger than 6 months are exclusively breastfed. [2] The low prevalence of 
breastfeeding is estimated to cost high income countries $231 billion (0.5% of gross national income) 
annually.[1] Policy makers in high income countries are seeking effective and cost-effective 
interventions to encourage breastfeeding.[3] 
 
Offering incentives to women to breastfeed have been identified as an effective intervention to 
increase breastfeeding and have been implemented in the US,[4] France,[5] and Canada.[6] The first  
ever RCT of a financial incentive for breastfeeding was conducted  among 36 low income Puerto 
Rican mothers who had initiated breastfeeding. This USA based RCT found higher rates of  continued 
breastfeeding in the intervention group compared with control (89% vs 44% at 1 month; 89% vs 17%, 
at 3 months; 72% vs 0%, at 6 months).[4] The authors recommended large scale studies to assess 
clinical and cost-effectiveness of incentive based breastfeeding interventions. 
 
The first UK based RCT of financial incentives for breastfeeding was conducted as part of the 
Nourishing Start for Health (NOSH) project [7]. This project developed and then trialled a structured 
population level financial incentive for breastfeeding intervention that offered shopping vouchers to 
women if their infant was receiving  breastmilk. The intervention was offered to all women living in 
areas with low breastfeeding prevalence (<40% at 6–8 weeks) in five local authority districts in the 
north of England. Up to five vouchers (£40 each) were offered to women if their baby was receiving 
breastmilk at the following ages:  2 days, 10 days, 6 weeks, 3 months and 6 months.  
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To date no cost effectiveness studies of financial incentives for breastfeeding have been identified.[8]  
However, Moran et al’s[3], review of breastfeeding incentive programmes, found eight studies with 
implementation costs data (but no cost effectiveness estimates). To ensure the efficient allocation of 
resources in health systems, global and national public health decision makers need information on 
the value for money of these interventions. The WHO Breastfeeding Policy Brief [9] identifies the 
need ‘to increase attention to, investment in, and action for a set of cost-effective interventions and 
policies, that can help Member States and their partners’ to increase breastfeeding and reach the WHO 
Global 2025 breastfeeding target of at least 50% of all infants being exclusively breastfed in the first 6 
months.   
 
This study, to the best of our knowledge examines, for the first time, the cost effectiveness of offering 
an area level financial incentive for breastfeeding intervention in a general population. Conducted 
alongside a large cluster (ward) RCT (Trial registration number ISRCTN44898617), the analyses 
examined the within-trial cost-effectiveness of financial incentive for breastfeeding in areas with low 
breastfeeding rates in the UK.  
 
 
Methods  
The within-trial cost-effectiveness analysis compared the cost and benefits (in terms of babies  
receiving breastmilk) of offering financial incentives to women over a 6-month period post birth  
versus  control (no offer), from a healthcare provider perspective.  The health outcome of interest was  
babies breastfed at 6–8week and cost-effectiveness was reported as cost per additional baby breastfed  
over the four quarters of the one year trial. Whilst data unavailability precluded estimating  
effectiveness at 6 months, total costs of vouchers were included in the analysis because  
the offer of vouchers up to 6 months was provided to participants at the outset of the trial and  
could therefore had impacted on the take up and duration of breastfeeding. The protocol  
planned cost-effectiveness analysis [10] was published prior to the analysis.  The Trial Steering  
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Committee approved changes from protocol to analyses.  Changes were necessary because logistical  
and data constraints precluded; (a) the collection of area-level data on hospital admissions (related to  
gastrointestinal infection , otitis media, respiratory tract infections and atopic eczema), and (b) beyond  
trial modelling of the long term cost effectiveness of the intervention. The trial protocol was approved  
by the National Health Service and local authority Research Governance and Research Ethics  
Committees (REC reference: 13/WM/0299). 
 
The total costs of providing the intervention in the trial included set up (website development, design 
and planning, booklet production, procurement, initial local engagement, and staff induction) and 
delivery costs (including; vouchers, processing of claims).  Resource use data were extracted from 
trial management records, computer-based diaries, and interviews with the trial manager. Resources 
were valued using national tariffs (e.g. [11]) to increase generalisability.  The unit costs of the 
vouchers were obtained from administrative records. Costs are expressed in pounds sterling (2015-
16), using the Hospital & Community Health Service (HCHS) inflation index where appropriate.[11] 
As the trial was within one year, a discount rate was not applied. 
 
Multivariable regression models adjusting for baseline variables and potential imbalances in treatment 
group were used to generate the incremental cost-effectiveness estimates.[12]  A generalised linear 
model using Poisson distributional family (and robust standard errors) was fitted to generate the cost 
per ward/trial arm and incremental cost per ward. As the control areas had zero cost, a constant value 
of £0.001 was added to observations for model convergence. Cost per baby/trial arm was derived by 
dividing the estimated mean cost per ward by the number of babies per ward. A negative binomial 
model was used to estimate the intervention effect following Relton et al.[7] albeit with different 
estimator. The outcome used in Relton et al.[7], percentage point increase in breastfeeding outcome, 
is a relative measure and not applicable to cost-effectiveness analysis.   
 
To provide  estimates of uncertainty, the ‘margins method’ generated sample means, by trial arm, for 
costs and breastfeeding.[12]  The choice of distributional family for models was based on modified 
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Park test [12] and comparison of observed and predicted values. The covariates of the models 
included correlates of breastfeeding related outcomes [7,13-14]: deprivation (IMD) score for the 
wards, baseline breastfeeding rate, and ethnicity, and the inverse of the variance of breastfeeding rate 
(to account for the number of births in relation to breastfeeding). The choice of covariates was based 
on a literature review conducted as part of this study to identify the potential predictors of 
breastfeeding related outcomes.   
 
Results are reported as cost per additional baby breastfed at 6-8 weeks. Deterministic sensitivity 
analyses assessed different components of total cost: (a) cost of routinely rolling out the scheme 
(covering induction and delivery costs); and (b) exclusion of the cost of voucher -  this was to 
demonstrate the impact of assuming cost of vouchers is a ‘transfer payment’ (i.e. giving women 
vouchers without any service in exchange); and therefore not includable in an economic evaluation. 
Probabilistic sensitivity analysis estimated the precision of the estimates of cost and breastfeeding and 
investigated the robustness of potential differences in each.  Bootstrap techniques (n=2000) based on 
regression models for costs and breastfeeding rates were employed to generate a sample of 
incremental costs and effects from an empirical distribution. This provided a measure of the 
probability that the intervention is cost-effective, at varying willingness to pay (WTP) values for 
changes in breastfeeding.   
 
Results 
Within trial cost-effectiveness 
Table 1 shows the descriptive statistics (unadjusted estimates). The total cost of providing the 
intervention in 46 wards, over 12 months and 5398 births in the period, was £462,600 with an average 
cost per ward of £9,989 (Standard deviation (SD) £5538) and per baby of £91 (SD £22.40) (Table 1). 
Delivery costs constituted 86%, followed by recruitment (8%), set up (5%), and training (1%). The 
highest individual contributors were vouchers (74%; £342,840) and initial local engagement costs 
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(4%; £19,598).  Total cost per ward ranged from £2,523 to £31,255 (Supplementary 1a-c). The 
control wards had no cost. 
 
 
{Table 1 here} 
 
 
Table 2 shows the regression-based estimates for costs, effects and incremental cost-effectiveness. 
Compared with control, the costs were higher for intervention wards (+£9738, 95%CI £8,520 to 
£10,957). Supplementary 2-3 show the regression based estimates. 
 
At baseline, area-level breastfeeding prevalence at 6-8 weeks was 27.4 (95% CI, 25.2-29.6) in control 
and 28.7 (95% CI, 26.7-30.6) in the intervention areas. At follow up (for April 1, 2015, to March 31, 
2016), area-level breastfeeding prevalence at 6-8 weeks was 31.7% (95% CI, 29.4-34.0) in control 
areas and 37.9% (95% CI, 35.0-40.8) in intervention areas [7]. The adjusted difference between 
intervention and control was 5.7 percentage points (95% CI, 2.7-8.6; P < .001), resulting in 10 (95% 
CI 6 to 14) more additional babies breastfed in the intervention wards (39 vs 29). The cost per 
additional baby breastfed at 6-8 weeks was £974. Thus, at a cost per QALY threshold of £20,000 
(recommended in England), an additional breastfed baby would need to show a lifetime total QALY 
gain to the infant and/or mother of 0.05 to justify the intervention cost. The required QALY gain 
decreases further to 0.03 if the threshold is £30,000.  
 
Deterministic sensitivity analyses (Table 2) show that voucher-only cost per additional baby breastfed 
at 6-8 weeks is £725 and £250 when only non-voucher costs are considered. Assuming the 
intervention is rolled out; the cost per additional baby breastfed will be £840.  Probabilistic sensitivity 
analysis indicates that if decision makers’ WTP for additional breastfed baby is £1000, the 
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intervention has 54% chance of being cost-effective (Figure 1). At a WTP of £1500, the probability of 
intervention being cost-effective increases to 94% and to 99% if the WTP is £2000.  
 
{Table 2 here} 
{Figure 1 here} 
 
 
Discussion   
During the one year trial, the total cost of offering financial incentives for 5,398 mother-infant dyads 
living in 46 areas with low breastfeeding prevalence was £462,600. Intervention areas compared with 
control required an additional cost (adjusted estimates) of £9,738 (CI 95% £8,520 to £10,957) per 
ward, equivalent of £83 (95% CI £73 to £93) per baby. Compared with control areas, the intervention 
areas reported 10 more breastfed babies (95% CI 6 to 14) at 6-8 weeks per ward (39 vs 29). The mean 
cost per additional baby breastfed at 6-8 weeks was £974. There is a 54% chance of the scheme being 
considered cost-effective if decision-makers were willing to pay £1000 per additional baby breastfed. 
Sensitivity analyses did not change this conclusion. 
 
These findings feed into a sparse and mixed evidence base on cost-effectiveness of interventions to 
increase breastfeeding.[15] One UK study reported that breastfeeding groups facilitated by a health 
professional led to higher costs (£5 per attendance) and a lower breastfeeding rate at 6-8 weeks (-
4%).[16]. Other studies showed that more intensive support and contact with health professionals, 
offer good value for money with Rice et al [17] showing such interventions are cheaper and more 
effective.  Hoddinott et al[18] compared the cost effectiveness of team (proactive) and women-
initiated (reactive) telephone support  for breastfeeding after discharge compared with reactive only 
and  reported an incremental cost per additional woman breastfeeding of £87.   
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This is the first study to examine the cost effectiveness of a financial incentive for breastfeeding 
intervention. The data on cost and effectiveness were sourced from a cluster RCT with 92% follow-
up. The resource use data for costing were collected prospectively using mostly logging system and 
computer-based records. This method led to minimal errors with respect to ascertainment of resource 
use and no missing data, a rarity in trial-based economic evaluations. [19] 
 
There are a number of limitations to this analysis.  First, breastfeeding has a wide range of benefits for 
both mothers and babies in both the short and longer term.[1] This analysis did not account for data on 
health service use or utility estimates and this limits the comparison with non-breastfeeding 
programmes in the health sector.  Second, the lack of data on the longer term benefits of breastfeeding 
to both mother and child means that the value for money of the intervention is underestimated. 
Breastfeeding has health benefits to both mothers and babies over the whole life course.[1] Obtaining 
robust estimates of the life time costs and benefits of breastfeeding to both the mother and baby is 
difficult due to the need to model outcomes far into the future, and was outside the scope of this 
analysis.  
  
A 2012 comprehensive review by Renfrew and colleagues found a clear association between 
increased breastfeeding and reduced cases of necrotising entercolitis in preterm babies, acute otitis 
media, lower respiratory tract infections and gastrointestinal infections, which was of sufficient 
quality to allow the estimation of the economic impacts of improved breastfeeding rates. [20] They 
showed that 45% of women exclusively breastfeeding for 4 months and 75% of babies in neonatal 
units being breastfed at discharge can lead to 3,285 fewer gastrointestinal infection related admissions 
and 10,637 fewer GP consultations (over £3.6 million treatment costs saving yearly); 5,916 fewer 
lower respiratory tract infection related hospital admissions and 22,248 fewer GP consultations (over 
£6.7 million treatment cost saving yearly);  21,045 fewer acute otitis media related general practice 
consultations (over £750,000 treatment cost saving yearly); and 361 fewer cases of necrotising 
entercolitis (over £6 million treatment cost saving yearly).  The application of these cost savings to the 
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NOSH data is, however, challenged by the specific diseases included within the cost estimates.  For 
example, the estimate on necrotising entercolitis was based on preterm babies within the neonatal 
intensive care unit (ICU).  It would be inappropriate to attribute this cost savings to the increase in 
breastfeeding within the NOSH trial, as the intervention was not targeted at mothers of preterm 
infants, and breastfeeding rates within the ICU were not assessed within the trial.  
 
However, although evidence supported an association between increased breastfeeding and improved 
cognitive outcomes, reduced early obesity and reduced Sudden Infant Death Syndrome (SIDS), the 
available literature was not of sufficient quality to allow estimation of the scale and scope of the risk 
reduction with precision.  With respect to the association between breastfeeding and other diseases 
such as asthma, diabetes and cardiovascular disease, the strength of the evidence was also deemed not 
sufficient to allow estimation of the risk reduction and economic impact.  Further well designed 
studies are needed which include adequate follow up of outcomes, accurate definition and 
measurement of breastfeeding and appropriate adjusting for confounding to inform the estimation of 
the long term health and economic impacts of improved breastfeeding. 
 
With respect to quantifying how reasonable the 0.05 QALY gain over lifetime is (estimated to justify 
the intervention cost), with currently available data, this is difficult to do.  The short term benefits on 
acute otitis media, lower respiratory tract infection and gastrointestinal infections are generally 
associated with mild sequelae within the UK and are of limited duration thereby resulting in only 
small utility deficits. [20-24] On the other hand, some of the longer term sequelae, which do not have 
adequate data available currently to quantify accurately the relative risk reduction associated with 
breastfeeding as listed above, would be associated with greater QALY deficits; however, many occur 
later in life and therefore the benefits and costs would be reduced due to discounting.  Without an 
accurate estimate of the risk reduction associated with the increase in breastfeeding achieved within 
the NOSH trial, it is not possible to model the impact on the incidence of long-term outcomes and 
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consequently the potential QALY gain. Future studies are recommended to measure the short and 
long-term health impact of interventions.  
 
Our analysis was based on the evidence from one trial, which tested a single permutation of the idea 
of offering financial incentives to mothers to breastfeed. Future research is needed to help optimise 
this idea - testing a number of different variations. For example, would a universal single payment of 
£50 to mothers for exclusive breastfeeding at 6-8 weeks be more or less effective in increasing 
breastfeeding rates?  Additionally, the data on breastfeeding was based on clinician reports collected 
as part of country-wide public health monitoring purposes. The validity of these reports are not 
usually assessed .[7] and therefore the use of objective measures of breastfeeding should be 
considered in future research.   
 
This study provides information to help inform public health guidance on breastfeeding. 
Implementing financial incentives to increase breastfeeding in areas with low breastfeeding 
prevalence could offer value for money if policy makers are willing to pay £974 (or more) per 
additional baby breastfed. To make the economic case unequivocal, more research is required to 
provide effectiveness data on financial incentives for breastfeeding beyond 6-8 weeks and 
epidemiological evidence on the varied health benefits of breastfeeding to both the baby and mother. 
This will allow the incorporation of long term health benefits of breastfeeding in an economic analysis 
and facilitate the comparison of financial incentives for breastfeeding with a wide range of other 
public health programmes and healthcare technologies.  
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List of Tables  
 
Table 1: Average costs of intervention arm (£’sterling 2015/16) 
Activities Activities  Average cost 
per ward (SD) 
n=46 
Average cost 
per baby (SD) 
n=5,398 
Set up 
 
 
 
Preparation of booklets describing the scheme £336 (0) £2.86 (0) 
Design of intervention £96 (0) £0.82 (0) 
Development of the website with information about 
the scheme – including the postcode calculator 
£64 (0) £0.55 (0) 
Procurement of the vouchers from vendors 
(supermarkets and Love2shop) 
£39 (0) £0.33 (0) 
Initial local engagement £426 (371) £7.34 (9.17) 
Advertisement £394 (0) £3.36 (0) 
Training/ Induction sessions for health visitors and 
midwives  
£131 (70) £1.65 (1.22) 
Delivery Vouchers £7453 (5028) £64.44 (18) 
Processing time for claim forms £317 (214) £2.74 (0.77) 
Information packs (including the booklets 
describing the scheme) 
£283 (148) £3 (1.46) 
Delivery of letters to mothers £189 (122) £2.10 (0.76) 
Costs of telephone, texts for processing claims £166 (0) £1.41 (0) 
Processing time for applications to join the NOSH 
scheme 
£93 (60) £0.84 (0.30) 
Total cost  £9989 (5538) £91.45 (22.38) 
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Table 2: Regression estimates for costs, effects, and cost effectiveness (£’sterling 2015/16) 
 Control (46 wards; 
4612 mother-infant 
dyads) 
Intervention (46 wards; 
5398 mother-infant 
dyads) 
Mean  (95% CI) Mean  (95% CI) 
Base case analysis 
Total cost per ward (£)  £0 (0, 0) £9738  (8520, 10957) 
Incremental cost(£) -  £9738  (8520, 10957) 
Percentage of babies breastfed at at 6-8 weeks 
per ward 
31.7% (29.4, 34.0) 37.9%  (35.0, 40.8) 
Total number of babies breastfed at 6-8 weeks 
per ward 
29 (27,32) 39 (36,43) 
Incremental number of breastfed babies -  10 (6,14) 
Cost per additional baby breastfed at 6-8 
weeks (£) 
- 
 
 £974 
Deterministic sensitivity analyses 
Assuming that the provision of vouchers is 
the only accruable to the intervention  
   
Total voucher cost per ward (£)  £0 (0, 0) £7251  (6117, 8385) 
Incremental non voucher cost(£) -  £7251  (6117, 8385) 
Total number of babies breastfed at 6-8 weeks 
per ward 
29 (27,32) 39 (36,43) 
Incremental breastfeeding -  10 (6,14) 
Voucher cost per additional  baby breastfed at 
6-8 weeks (£) 
-  £725 
Assuming that the provision of vouchers will 
be free of charge to the providers  
   
Total non-voucher cost per ward (£)  £0 (0, 0) £2498  (2355, 2638) 
Incremental non-voucher cost(£) -  £2498  (2355, 2638) 
Total number of babies breastfed at 6-8 weeks 
per ward 
29 (27,32) 39 (36,43) 
Incremental breastfeeding -  10 (6,14) 
Non-voucher cost per additional  baby 
breastfed at 6-8 weeks (£) 
-  £250 
Cost of routinely rolling out intervention    
Total roll out cost per ward (£)  £0 (0, 0) £8402  (7154, 9649) 
Incremental roll out cost(£) -  £8402 (7154, 9649) 
Total number of babies breastfed at 6-8 weeks 
per ward  
29 (27,32) 39 (36,43) 
Incremental breastfeeding -  10 (6,14) 
Roll cost per additional baby breastfed at 6-8 
weeks (£) 
  £840 
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